Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations

BACKGROUND: Tenofovir alafenamide fumarate (TAF) was approved for HBV treatment in China in 2018. Despite higher antiviral efficacy and less impact on renal function and bone mineral density, the pharmacokinetic profiles of TAF are highly variable. The objectives of this study were to investigate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xue, Tan, Xin-Yi, Cui, Xue-Jun, Yang, Ming, Chen, Chao, Chen, Xiao-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525415/
https://www.ncbi.nlm.nih.gov/pubmed/34703277
http://dx.doi.org/10.2147/PGPM.S329690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525415/
https://www.ncbi.nlm.nih.gov/pubmed/34703277
http://dx.doi.org/10.2147/PGPM.S329690

Ejemplares similares